From: Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment
 | patients, n (%) | Subtype I | Subtype II | p value |
---|---|---|---|---|
Age (year) | ||||
 Mean | 56 | 54 | 60 |  |
 Range | 35–73 | 35–73 | 41–71 |  |
Race | ||||
 White | 20 | 14 | 6 |  |
 Black or African American | 4 | 2 | 2 |  |
 Asian | 1 | 1 | 0 |  |
 Unknown | 4 | 3 | 1 |  |
Tumor weight | Â | Â | Â | 0.4 |
 Mean | 341.83 | 303.8 | 426.33 |  |
 Range | 55–1100 | 58–1100 | 55–1077 |  |
Treatment best response | Â | Â | Â | 0.04 |
 Complete Response | 8(27%) | 6 | 2 |  |
 Partial Response | 2(7%) | 0 | 2 |  |
 Clinical Progressive Disease | 4(14%) | 4 | 0 |  |
 Unknown | 15(52%) | 10 | 5 |  |
Metastatic disease confirmed | Â | Â | Â | 0.18 |
 YES | 10 (34%) | 5 | 5 |  |
 NO | 11 (38%) | 9 | 2 |  |
 Unknown | 8 (28%) | 6 | 2 |  |
Contiguous organ invaded | Â | Â | Â | 0.24 |
 YES | 4(14%) | 2 | 2 |  |
 NO | 8 (28%) | 7 | 1 |  |
 Unknown | 17 (58%) | 11 | 6 |  |
Necrosis percent | Â | Â | Â | 0.52 |
 Mean | 20.33 | 23.5 | 14 |  |
 Range | 0–50 | 1–50 | 0–33 |  |